1. Home
  2. LQDA vs BASE Comparison

LQDA vs BASE Comparison

Compare LQDA & BASE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LQDA
  • BASE
  • Stock Information
  • Founded
  • LQDA 2004
  • BASE 2011
  • Country
  • LQDA United States
  • BASE United States
  • Employees
  • LQDA N/A
  • BASE N/A
  • Industry
  • LQDA Biotechnology: Pharmaceutical Preparations
  • BASE EDP Services
  • Sector
  • LQDA Health Care
  • BASE Technology
  • Exchange
  • LQDA Nasdaq
  • BASE Nasdaq
  • Market Cap
  • LQDA 856.5M
  • BASE 834.0M
  • IPO Year
  • LQDA 2018
  • BASE 2021
  • Fundamental
  • Price
  • LQDA $10.65
  • BASE $20.93
  • Analyst Decision
  • LQDA Strong Buy
  • BASE Buy
  • Analyst Count
  • LQDA 8
  • BASE 13
  • Target Price
  • LQDA $27.14
  • BASE $23.31
  • AVG Volume (30 Days)
  • LQDA 773.7K
  • BASE 281.0K
  • Earning Date
  • LQDA 11-13-2024
  • BASE 12-03-2024
  • Dividend Yield
  • LQDA N/A
  • BASE N/A
  • EPS Growth
  • LQDA N/A
  • BASE N/A
  • EPS
  • LQDA N/A
  • BASE N/A
  • Revenue
  • LQDA $15,610,000.00
  • BASE $198,818,000.00
  • Revenue This Year
  • LQDA N/A
  • BASE $17.65
  • Revenue Next Year
  • LQDA $227.73
  • BASE $15.17
  • P/E Ratio
  • LQDA N/A
  • BASE N/A
  • Revenue Growth
  • LQDA N/A
  • BASE 21.00
  • 52 Week Low
  • LQDA $6.69
  • BASE $13.53
  • 52 Week High
  • LQDA $16.99
  • BASE $32.00
  • Technical
  • Relative Strength Index (RSI)
  • LQDA 52.84
  • BASE 77.20
  • Support Level
  • LQDA $9.93
  • BASE $19.04
  • Resistance Level
  • LQDA $10.95
  • BASE $19.85
  • Average True Range (ATR)
  • LQDA 0.45
  • BASE 0.72
  • MACD
  • LQDA -0.02
  • BASE 0.25
  • Stochastic Oscillator
  • LQDA 67.14
  • BASE 89.96

About LQDA Liquidia Corporation

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.

About BASE Couchbase Inc.

Couchbase Inc provides a modern cloud database that offers the robust capabilities required for business-critical applications on a scalable and available platform. It empower developers and architects to build, deploy and run mission-critical applications. Couchbase delivers a high-performance, flexible and scalable modern database that runs across the data center and any cloud. Geographically, the company generates a majority of its revenue from the United States.

Share on Social Networks: